Octave Bioscience
Blood biomarkers that reveal hidden MS disease
Menlo Park, California, US
Octave Bioscience is a precision care company that offers a biomarker-driven testing platform to provide objective insights for monitoring and treating neurodegenerative diseases.
How We Help
Problem Statement
The company addresses the challenge of monitoring and making treatment decisions for neurodegenerative diseases by providing objective, data-driven insights into disease activity.
Core Technology
Biomarker Testing & AI
Key Differentiators
First-of-its-kind multi-analyte blood test for Multiple Sclerosis (MS) disease activity.; Combines biomarker testing with artificial intelligence to provide clinically actionable insights.
Clinical Focus
Neurology
Company Info
- Business Model
- B2B
- Total Funding
- 124,000,000
- Website
- octavebio.com
Categories
Technologies
Clinical & IP
Clinical Validation
18-protein MSDA Test validated in Nature Communications (2024), Proteomics Clinical Applications (2023), and Clinical Immunology (2023). CLIA-certified, NY State CLEP-certified. Real-world data: 19.4% of clinician decisions changed post-test; patients with high MSDA scores 4x+ more likely to have inflamed lesions.
MedStartr Index Score
?What do you think of Octave Bioscience?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.